Ad\"yuvantnaya terapiyav lechenii gastrointestinal'nykh stromal'nykh opukholey


如何引用文章

全文:

详细

Приведены данные об адъювантной терапии при гастроинтестинальных стромальных опухолях. Обсуждаются факторы прогноза: локализация, размер, митотический индекс. Приводятся североамериканские и европейские рекомендации по лечению стромальных опухолей.

作者简介

M Nikulin

ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва

I Stilidi

ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва

参考

  1. Kingham T, De Matteo R. Multidisciplinary Treatment of Gastrointestinal Stromal Tumors. Surg Clin N Am 2009; 89: 217–33.
  2. De Matteo R, Ballman K, Antonescu C et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double - blind, placebo - controlled trial. www.thelancet.com 2009; 373: 1097–104.
  3. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular - targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341–6.
  4. Rutlowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304–11.
  5. Fletcher C, Berman J, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459–65.
  6. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_det ail_view&confID=53&abstractID=10450
  7. SSG XVIII/AIO. www.ClinicalTrials.gov:identifier: NCT00116935
  8. EORTC62024.www.ClinicalTrials.gov:identifier:NCT00103168
  9. Eisenberg B, Harris J, Blanke C et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN:665. J Surg Oncol 2009; 99: 42–7.
  10. NCCN Practice Guidelines in Oncology. 2009; 2.
  11. Casali P, Jost J, Reichardt P et al. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow - up. Ann Oncol 2009; 20 (Suppl. 4): iv64–7.
  12. Heikki Joensuu. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411–9.
  13. Raut C, De Matteo R. Prognostic Factors for Primary Gist: Prime Time for Personalized Therapy. Ann Surg Oncol 2008; 15 (1): 4–6.

版权所有 © Consilium Medicum, 2009

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##